Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WELL Health Technologies Corp T.WELL

Alternate Symbol(s):  T.WELL.DB | WHTCF

WELL Health Technologies Corp. is a practitioner-focused digital healthcare company. The Company develops technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. Its business units include Canadian Patient Services, WELL Health USA Patient Services and SaaS and Technology Services. WELL Health USA Patient and... see more

TSX:WELL - Post Discussion

View:
Post by retiredcf on Aug 13, 2024 9:17am

TD

CIRCLE MEDICAL SURPASSES US$100MM REVENUE RUN-RATE WITH 65% ORGANIC GROWTH

THE TD COWEN INSIGHT

Organic growth at Circle is sharply re-accelerating, as it continues to gain market share profitably. The very strong performance in July indicates the business is tracking well ahead of our forecasts, better positioning WELL to deliver better-than-expected Q2 results tomorrow (continuing its >4-year streak), and it should help bolster its potential value to WELL with a possible sale soon.

Impact: SLIGHTLY POSITIVE

Exceeds $100mm revenue run-rate as growth is rapidly re-accelerating. Based on its July revenue run-rate of $8.87mm, Circle has now surpassed the $100mm annualized revenue run-rate mark for the first time, up dramatically from ~$5mm in ARR <4 years ago when WELL bought its majority stake.

Organic growth in July was 65% y/y, well above the 39% pace in F2023. Assuming no further m/m growth in Q3/F24 (unlikely in our view), the current run-rate is ~14% above our Q3/F24 revenue forecast for Circle and represents ~2% upside to our current Q3/F24 revenue forecast for WELL.

Strategic review continues. WELL continues to work with advisors to assess strategic alternatives for Circle to help unlock value for shareholders. As communicated by management last quarter (link), WELL believes it could make a related announcement on the strategic process (e.g., a potential sale) in late F2024/early F2025, with WELL possibly making a similar announcement for Wisp this quarter.

Key AI partnerships and management hires. Circle also announced it is investing heavily in AI-powered solutions, including AI-powered scribes for documentation and compliance tools for clinical reviews. We believe it could help leverage WELL's AI solutions and investments.

The company also recently appointed Miguel Jette as its first Head of AI to lead its AI strategy, with Mr. Jette possessing over 20 years of experience in the field.

Circle also welcomed back one of its co-founders, Brent LaRue, as VP of Product and Patient Experience, who will focus on product design and enhance patient engagement and satisfaction. We note that Circle already maintains a 99% patient satisfaction rating based on industry CSAT surveys.

Comment by ahsh1kah on Aug 13, 2024 11:37am
Cowen and other analysts state; selling Circle and WISP will help unlock value for shareholders. The question is, which will benifet the shareholders most (for long term), using the net proceeds to pay debt or shares buyback (and even start paying dividend)?   
Comment by ahsh1kah on Aug 13, 2024 12:03pm
I know, there is pros and cons for each.   Copilot answered my question :) Deciding between debt repayment and stock buybacks involves a strategic evaluation of several factors. Here’s a breakdown of the key considerations:   1. Financial Health and Leverage   a- Debt Levels: Companies with high debt levels might prioritize debt repayment to reduce financial risk and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities